References: 1. Yen J, Chen S, Jenkins C, et al. BRCA1 promoter methylation in sporadic breast cancer patients detected by liquid biopsy. Poster presented at: American Association for Cancer Research Annual Meeting. April 14-19, 2023; Orlando, FL.
2. Kondrashova O, Topp M, Nesic K, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018;9(1):3970. doi:10.1038/s41467-018-05564-z
3. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92(7):564-569. doi:10.1093/jnci/92.7.564
4. Staaf J, Glodzik D, Bosch A, et al. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat Med. 2019;25(10):1526-1533. doi:10.1038/s41591-019-0582-4
5. Guardant Health data on file. Guardant Health, Inc. Redwood City, CA.
6. Elazezy M, Prieske K, Kluwe L, et al. BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer. Mol Oncol. 2021;15(12):3615-3625. doi:10.1002/1878-0261.13108
BRCA1 promoter methylation and pathogenic genomic alterations
in homologous recombination and repair (HRR) genes are
mutually exclusive in cancer patients.1-4
Predict Clinical Response
CHARACTERIZE CANCER
Promoter methylation biomarkers can
expand patient reach
or predict response.1,2
Predict clinical response to DNA-damaging chemotherapy
with blood-based BRCA1 promoter methylation.2
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma